Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Advaxis, Sellas Life Sciences deal

March 2, 2017 8:51 PM UTC

Advaxis granted Sellas rights to use Advaxis’ Listeria monocytogenes (LM)-based antigen delivery technology to develop Sellas’ cancer immunotherapeutic galinpepimut-S. Advaxis will conduct preclinical trials of the combination, and Sellas will be responsible for clinical development and commercialization. Advaxis is eligible for up to $358 million in milestones, plus single- to low-double-digit royalties. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article